Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

被引：5
|
作者：
Tahara, Makoto
Kiyota, Naomi
Yokota, Tomoya
Hasegawa, Yasuhisa
Muro, Kei
Takahashi, Shunji
Onoe, Takuma
Homma, Akihiro
Taguchi, Jun
Suzuki, Masami
Minato, Koichi
Yane, Katsunari
Ueda, Shinya
Hara, Hiroki
Saijo, Ken
Yamanaka, Takeharu
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Kobe Univ Hosp, Div Med Oncol & Hematol, Dept Med, Kobe, Hyogo, Japan
[3] Grad Sch Med, Kobe, Hyogo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Caner Ctr, Nagoya, Aichi, Japan
[6] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[7] Ctr Canc Chemotherapy, Tokyo, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan
[10] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan
[11] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[12] Gunma Prefectural Canc Ctr, Ota, Japan
[13] Gunma Prefectural Canc Ctr, Div Resp Med, Ota Shi, Japan
[14] Nara Hosp Kinki Univ, Fac Med, Ikoma, Japan
[15] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[16] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[17] Tohoku Univ, Sendai, Miyagi, Japan
[18] Yokohama City Univ, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6026
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
    Guigay, J.
    Fayette, J.
    Dillies, A. F.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. P.
    Zanetta, S.
    Pointreau, Y.
    Bozec Le Moal, L.
    Henry, S.
    Schilf, A.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1941 - 1947
  • [22] Paclitaxel and carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. A phase II study.
    Hiller, S
    Mergenthaler, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [23] Phase II study of dasatinib in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma
    Stabile, Laura P.
    Egloff, Ann Marie
    Zhou, Pei
    Gooding, William E.
    Grandis, Jennifer R.
    Bauman, Julie E.
    CANCER RESEARCH, 2016, 76
  • [24] Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
    Yoshino, Takayuki
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Monden, Nobuya
    Homma, Akihiro
    Okami, Kenji
    Onozawa, Yusuke
    Fujii, Masato
    Taguchi, Takahide
    de Blas, Barbara
    Beier, Frank
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 524 - 531
  • [25] Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carboplatin for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Saba, Nabil F.
    Hurwitz, Selwyn J.
    Magliocca, Kelly
    Kim, Sungjin
    Owonikoko, Taofeek K.
    Harvey, Donald
    Ramalingam, Suresh S.
    Chen, Zhengjia
    Rogerio, Jackie
    Mendel, Jennifer
    Kono, Scott A.
    Lewis, Colleen
    Chen, Amy Y.
    Higgins, Kristin
    El-Deiry, Mark
    Wadsworth, Trad
    Beitler, Jonathan J.
    Shin, Dong M.
    Sun, Shi-Yong
    Khuri, Fadlo R.
    CANCER, 2014, 120 (24) : 3940 - 3951
  • [26] A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
    Sabichi, A. L.
    Kies, M. S.
    Glisson, B. S.
    Lu, C.
    Ginsberg, L. E.
    Bartos, C. I.
    Feng, L.
    Tran, H. T.
    Lippman, S. M.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [28] Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
    Hsieh, M-C.
    Wang, C-C.
    Yang, C-C.
    Yeh, S-A.
    Lien, C-F.
    Wang, C-C.
    Shih, Y-C.
    Tsai, Y-F.
    Hwang, T-Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S1350 - S1351
  • [29] Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
    Hitt, R.
    Irigoyen, A.
    Nunez, J.
    Grau, J.
    Garcia Saenz, J.
    Pastor, M.
    Jara, C.
    Garcia Giron, C.
    Hidalgo, M.
    Cruz Hernandez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    Vermorken, J. B.
    Licitra, L.
    Stoehlmacher-Williams, J.
    Dietz, A.
    Lopez-Picazo, J. M.
    Hamid, O.
    Hossain, A. M.
    Chang, S. -C.
    Gauler, T. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2877 - 2883
12345